氨氯地平联合复方阿米洛利与联合替米沙坦治疗轻、中度高血压的疗效与安全性Meta分析  

Meta-analysis of therapeutic efficacy and safety of amlodipine plus amiloride/hydrochlorothiazide and amlodipine plus telmisartan in the treatment of mild-to-moderate hypertension

作　　者：左珊如 刘世坤[2] 左笑丛[2] 李兵[2] 吴翠芳[2] 李佐军[2] 王春江[2] 邓珍珍[2] 马玉桃[1,2] 

机构地区：[1]中南大学药学院 [2]中南大学湘雅三医院药剂科

出　　处：《中国临床药理学与治疗学》2015年第1期70-74,共5页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的：采用Meta分析系统评价氨氯地平联合复方阿米洛利与氨氯地平联合替米沙坦治疗轻、中度高血压的临床疗效及安全性的差异。方法：以氨氯地平、复方阿米洛利、替米沙坦、高血压为主题词,检索Pubmed、Web of Science、中国知网（CNKI）和万方数据库,收集氨氯地平联合复方阿米洛利或替米沙坦治疗高血压的相关文献,在严格的文献质量评价基础上,应用Meta分析对纳入的文献：研究氨氯地平分别联合复方阿米洛利、替米沙坦治疗轻、中度高血压的有效性与安全性,进行同质性检验及合并效应量的估计。结果：共纳入13篇文献,16 192例研究对象,其中复方阿米洛利组8 098例,替米沙坦组8 094例。有效性的同质检验：χ^2=14.50,df=12,P=0.27;安全性的同质性检验：χ^2=5.86,df=7,P=0.56。两者合并效应量的估计,有效性：OR合并=0.93,95%可信区间为0.81～1.06。安全性OR合并=1.23,95%可信区间为1.04～1.45。结论：氨氯地平联合复方阿米洛利治疗轻、中度高血压有效性与氨氯地平联合替米沙坦无统计学差异,但安全性方面氨氯地平联合替米沙坦优于氨氯地平联合复方阿米洛利。AIM： To evaluate the clinical efficacy and safety of amlodipine plus amiloride/hydrochlo- rothiazide and amlodipine plus telmisartan in the treatment of mild-to-moderate hypertension by Me- ta-analysis. METHODS： Pubmed, Web of Science, CNKI and Wanfang Database were searched for combination of amlodipine plus amiloride/hydro- chlorothiazide and amlodipine plus telmisartan on hypertension treatment using the key words “amlo- dipine”, “amiloride/hydrochlorothiazide”, “telmis- artan” and “hypertension”, supplemented literature recourse method to retrieve. The effectiveness and safety of amlodipine plus amiloride/hydrochlorothia- zide and amlodipine plus telmisartan agents and o- verall effect tests based on strict quality evaluation of clinical trials. RESULTS： 13 literatures and 16 192 patients were included in this study, which consisted of 8 098 cases in amiloride/hydrochloroth-iazide group and 8 094 cases in telmisartan group. The result of homogeneity test of efficacy was：χ^2 = 14.50, df=12,P=0.27;while that of safety was 2 = 5.86, df = 7, P = 0.56. The combined ORs and 95% CIs were 0.93, 0.81 -- 1.06 for efficacy and 1.23,1.04-1.45 for safety, respectively. CONCLU- SION： There is no significant difference in therapeu- tic efficacy between amlodipine plus amiloride / hydrochlorothiazide and amlodipine plus telmisartan in the treatment of mild-to-moderate hypertension, but amlodipine plus telmisartan is safer and has less adverse reaction.

关 键 词：复方阿米洛利 氨氯地平 替米沙坦 轻 中度高血压 META分析 

分 类 号：R969.1[医药卫生—药理学]